A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer

Daito Noguchi; Toshiyuki Seki; Yutaro Kubonoya; Hiromi Komazaki; Hirokazu Ozone; Nozomu Yanaihara; Hirokuni Takano; Aikou Okamoto

doi:10.1016/j.gore.2021.100885

A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer

Gynecol Oncol Rep. 2021 Oct 23:38:100885. doi: 10.1016/j.gore.2021.100885. eCollection 2021 Nov.

Authors

Daito Noguchi¹, Toshiyuki Seki¹, Yutaro Kubonoya¹, Hiromi Komazaki¹, Hirokazu Ozone¹, Nozomu Yanaihara¹, Hirokuni Takano¹, Aikou Okamoto¹

Affiliation

¹ Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan.

Abstract

•This is the first report of aseptic meningitis due to immune checkpoint inhibitor treatment in endometrial cancer.•The meningitis was severe and relapsed multiple times unlike in other reported cases.•Oncologic outcome was excellent after overcoming this severe adverse event.

Keywords: Endometrial cancer; Immune checkpoint inhibitor; Immune-related adverse events; Meningitis; Pembrolizumab.

Publication types

Case Reports